Happy New Year from all of us at Pharmidex!
December 31, 2025

As we step into 2026, we’re proud to continue supporting our clients with local UK expertise delivered at an international scale.


At Pharmidex, we support programmes from discovery through to IND-enabling studies, helping teams progress confidently from concept to clinic. With integrated in vivo, bioanalysis and translational capabilities, everything is delivered under one roof in the UK, ensuring quality, continuity and efficiency at every stage.


2025 was one of the most challenging years our industry has faced, yet together we continued to deliver meaningful science, supporting nearly 1,000 projects and contributing to medicines that make a real difference to patients’ lives.


Thank you to our clients and partners for your continued trust.


We look forward to supporting innovation and high-quality science in the year ahead.

February 19, 2026
Science is serious… but Pancake Day is not. Yesterday we took a short pause from studies, data and reports to enjoy some well-earned pancakes together as a team. With Ramadan also beginning, we made sure there were plenty saved for colleagues breaking their fast later in the evening. At Pharmidex , we’re proud of the work we deliver, but we’re equally proud of the people behind it. Small moments like this remind us that strong teams are built not only in the lab, but around the table too. Thank you to everyone for your hard work and for making our culture what it is. 🙌
February 17, 2026
We’re proud to announce that Pharmidex has joined the Good Clinical Practice (GCP) Network , a global collaboration advancing ICH-GCP excellence in clinical research. For us, quality and data integrity are not box-ticking exercises, they are fundamental to credible science and responsible drug development. From pre-clinical research through to clinical delivery, we are committed to: • Regulatory rigour • Ethical conduct • Participant protection • Scientifically robust data Joining the GCP Network further strengthens that commitment. We look forward to contributing to a global community dedicated to raising the bar across clinical research.
February 12, 2026
Pharmidex now offers integrated in vivo CAR-T study support , combining robust in-life pharmacology with advanced f low cytometry –based cellular analysis. We support early-stage CAR-T and cell therapy programmes with translational data on efficacy, expansion, persistence and phenotype delivered through a single collaborative CRO partner. Let’s talk. 🌐 www.pharmidex.com
More Posts